Overview
Osteoporosis-oculocutaneous hypopigmentation syndrome is an extremely rare genetic condition that affects multiple body systems, primarily the bones, skin, and eyes. It is sometimes referred to as osteogenesis imperfecta with oculocutaneous hypopigmentation or a related overlapping condition. People with this syndrome have bones that are weaker than normal (osteoporosis), making them more prone to fractures, even from minor injuries or everyday activities. In addition, the skin and eyes have reduced pigmentation (hypopigmentation), meaning the skin may appear unusually pale and the eyes may have lighter coloring than expected for the family background. Some individuals may also experience vision problems related to the eye pigment changes. Because this condition is so rare, the full range of symptoms and the best treatment approaches are still being studied. Treatment is mainly supportive and focuses on managing bone fragility through medications that strengthen bones, physical therapy to maintain mobility, and protecting the skin and eyes from sun damage. Genetic counseling is recommended for affected families to understand the inheritance pattern and recurrence risk. Early diagnosis and a coordinated care team are important for improving quality of life.
Also known as:
Key symptoms:
Fragile bones that break easilyOsteoporosis (thin, weak bones)Unusually pale or light skinLight-colored eyesReduced pigmentation of the hairVision problemsSensitivity to sunlightShort stature or growth delaysBone painFrequent fractures from minor traumaPossible dental abnormalities
Clinical phenotype terms (12)— hover any for plain English
Autosomal recessive
Passed on when both parents carry the same gene change; often skips generations
Childhood
Begins in childhood, roughly ages 1 to 12
Treatments
No FDA-approved treatments are currently listed for Osteoporosis-oculocutaneous hypopigmentation syndrome.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for Osteoporosis-oculocutaneous hypopigmentation syndrome at this time.
New trials open frequently. Follow this disease to get notified.
Specialists
View all specialists →No specialists are currently listed for Osteoporosis-oculocutaneous hypopigmentation syndrome.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Osteoporosis-oculocutaneous hypopigmentation syndrome.
Community
No community posts yet. Be the first to share your experience with Osteoporosis-oculocutaneous hypopigmentation syndrome.
Start the conversation →Latest news about Osteoporosis-oculocutaneous hypopigmentation syndrome
No recent news articles for Osteoporosis-oculocutaneous hypopigmentation syndrome.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Questions for your doctor
Bring these to your next appointment
- Q1.What specific genetic testing should my family and I undergo?,How often should bone density be monitored, and what treatments can help strengthen bones?,Are there any activities my child should avoid to reduce fracture risk?,What sun protection measures are most important for the skin and eyes?,Should other family members be tested for this condition?,Are there any clinical trials or research studies we could participate in?,What specialists should be part of our ongoing care team?
Common questions about Osteoporosis-oculocutaneous hypopigmentation syndrome
What is Osteoporosis-oculocutaneous hypopigmentation syndrome?
Osteoporosis-oculocutaneous hypopigmentation syndrome is an extremely rare genetic condition that affects multiple body systems, primarily the bones, skin, and eyes. It is sometimes referred to as osteogenesis imperfecta with oculocutaneous hypopigmentation or a related overlapping condition. People with this syndrome have bones that are weaker than normal (osteoporosis), making them more prone to fractures, even from minor injuries or everyday activities. In addition, the skin and eyes have reduced pigmentation (hypopigmentation), meaning the skin may appear unusually pale and the eyes may ha
How is Osteoporosis-oculocutaneous hypopigmentation syndrome inherited?
Osteoporosis-oculocutaneous hypopigmentation syndrome follows a autosomal recessive inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does Osteoporosis-oculocutaneous hypopigmentation syndrome typically begin?
Typical onset of Osteoporosis-oculocutaneous hypopigmentation syndrome is childhood. Age of onset can vary across affected individuals.